CG Oncology, Inc. Common stock

CGONNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
78.42 USD
↘ 0.53 (0.67%)AT CLOSE (11:59 AM EDT)
78.50
↗ 0.08 (0.10%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
78.50
↗ 0.08 (0.10%)
🔴Market: CLOSED

CGON is currently priced at $78.41. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, CGON trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Aug 26, 2026.

Open?$78.29
High?$78.94
Low?$76.87
Prev. Close?$78.95
Volume?507.8K
Avg. Volume?817.8K
VWAP?$78.35
Rel. Volume?0.62x
Bid / Ask
Bid?$76.75 × 1.0K
Ask?$81.09 × 300
Spread?$4.34
Midpoint?$78.92
Valuation & Ratios
Market Cap?7.0B
Shares Out?88.6M
Float?68.9M
Float %?78.1%
P/E Ratio?N/A
P/B Ratio?6.75
EPS?-$2.53
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
142
Market Cap
7.0B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cgoncology.com
Listed
2024-01-25
Address
3000 PEGASUS PARK DRIVE
DALLAS, TX 75247
Phone: (949) 409-3700
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
21
Short Sent.?
44
Piotroski F-Score?0/9Weak
Altman Z-Score?73.45Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?16.33%High
Short Interest?11.2M
Days to Cover?14.9
Free Float68.9M
Avg Daily Volume757.6K
Settlement Date2026-08-14
Financial Health
Current Ratio?22.22Strong
Quick Ratio?22.20Strong
Cash Ratio?0.42Low
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
28
6.75FAIR▾
P/S?
Peers
100
S&P
3
1,116.12HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-27.8CHEAP▾
EV/Sales?
Peers
100
S&P
3
1,113.45HIGH▾
Returns & Efficiency
ROE?
S&P
7
-21.8%WEAK▾
ROA?
S&P
3
-20.7%WEAK▾
Cash Flow & Enterprise
FCF?$-179343000
Enterprise Value?$6.9B
Fundamentals ratios updated end of day
MarketsMoversWatchlist